| Literature DB >> 24438517 |
Stine Lund1, Birgitte B Nielsen, Maryam Hemed, Ida M Boas, Azzah Said, Khadija Said, Mkoko H Makungu, Vibeke Rasch.
Abstract
BACKGROUND: Applying mobile phones in healthcare is increasingly prioritized to strengthen healthcare systems. Antenatal care has the potential to reduce maternal morbidity and improve newborns' survival but this benefit may not be realized in sub-Saharan Africa where the attendance and quality of care is declining. We evaluated the association between a mobile phone intervention and antenatal care in a resource-limited setting. We aimed to assess antenatal care in a comprehensive way taking into consideration utilisation of antenatal care as well as content and timing of interventions during pregnancy.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24438517 PMCID: PMC3898378 DOI: 10.1186/1471-2393-14-29
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.007
Figure 1Procedures for selection of study population.
Recommended timing and content of antenatal visits
| | <16 weeks | 20–24 weeks | 28–32 weeks | 36–40 weeks |
| Confirm pregnancy and expected date of delivery | Assess maternal and fetal well-being | Assess maternal and fetal well-being | Assess maternal and fetal well-being | |
| | Classify women for basic ANC or more specialized care | Exclude PIH and anaemia | Exclude PIH and anaemia and multiple pregnancies | Exclude PIH, anaemia, multiple pregnancies and malpresentation |
| | Screen, treat and give preventive measures | Give preventive measures | Give preventive measures | Give preventive measures |
| | Develop a birth and emergency plan | Review and modify birth and emergency plan | Review and modify birth and emergency plan | Review and modify birth and emergency plan |
| | Advice and counsel | Advice and counsel | Advice and counsel | Advice and counsel |
| Blood pressure | Blood pressure | Blood pressure | Blood pressure | |
| | Haemoglobin | Haemoglobin | Haemoglobin | Haemoglobin |
| | Protenuria* | Protenuria* | Protenuria* | Protenuria* |
| | Bacteriuria** | Bacteriuria** | Bacteriuria** | Bacteriuria** |
| | HIV | | | |
| | Syphilis | | | |
| | Blood/Rh group** | | | |
| Tetanus toxoid*** | | Tetanus toxoid*** | | |
| | Iron and folate | Iron and folate | Iron and folate | Iron and folate |
| | | IPTp**** | IPTp**** | |
| ARV if eligible | ARV if eligible | ARV if eligible |
*Only nulliparous women, women with previous pre-eclampsia and women with diastolic blood pressure above 90. **Additional intervention for use in referral centres but not recommended as routine for resource-limited settings. *** TT1 at first antenatal care visit, TT2 at least four weeks after, TT3 at least six months later, TT4 at least 1 year later, TT5 at least one year later. Five doses are considered to give protection during the rest of the childbearing years. ****1 dose gestational week 16–28, 2 dose gestational week 28–40. There should be at least four weeks between doses. ANC = antenatal care, PIH = Pregnancy Induced Hypertension, IPTp = Intermittent Preventive Treatment in pregnancy.
Baseline characteristics of the study population. Values are numbers (%)
| | | |
| No | 12 | 12 |
| | | |
| No of women | 1311 | 1239 |
| Age | | |
| <19 | 107/1258 (9%) | 118/1197 (10%) |
| 20–24 | 310/1258 (25%) | 307/1197 (26%) |
| 25–29 | 371/1258 (29%) | 309/1197 (26%) |
| 30–34 | 248/1258 (20%) | 259/1197 (22%) |
| 35+ | 222/1258 (18%) | 204/1197 (17%) |
| Literacy | | |
| Can read very well | 3601298 (28%) | 384/1221 (31%) |
| Can read well | 447/1298 (34%) | 363/1221 (30%) |
| Can read some | 178/1298 (14%) | 174/1221 (14%) |
| Can read little | 86/1298 (7%) | 88/1221 (7%) |
| Cannot read | 227/1298 (18%) | 212/1221 (17%) |
| Education | | |
| No | 204/1278 (16%) | 220/1200 (18%) |
| Primary | 464/1278 (36%) | 440/1200 (37%) |
| Secondary and above | 569/1278 (45%) | 503/1200 (42%) |
| Other | 41/1278 (3%) | 37/1200 (3%) |
| Mobile phone status | | |
| Owns | 494/1307 (38%) | 439/1235 (36%) |
| Does not own | 813/1307 (62%) | 796/1235 (65%) |
| Residence status | | |
| Rural | 743/1311 (57%) | 730/1239 (59%) |
| Urban | 568/1311 (43%) | 509/1239 (41%) |
| Parity | | |
| Nullipara | 264/1290 (21%) | 233/1201 (19%) |
| 1–2 | 428/1290 (33%) | 356/1201 (30%) |
| 3–4 | 292/1290 (23%) | 297/1201 (25%) |
| 5+ | 306/1290 (24%) | 315/1201 (26%) |
| Gestational age at first antenatal care visit | | |
| <16 | 256/1310 (20%) | 329/1233 (27%) |
| 17–26 | 930/1310 (71%) | 814/1233 (66%) |
| 27–35 | 121/1310 (9%) | 87/1233 (7%) |
| 36+ | 3/1310 (0%) | 3/1233 (0%) |
| Complication last pregnancy according to mother | | |
| Yes | 89/1271 (7%) | 122/1271 (11%) |
| No | 918/1271 (72%) | 811/1271 (70%) |
| Nullipara | 264/1271 (21%) | 233/1271 (20%) |
Characteristics of primary and secondary outcomes
| | | |
| No of antenatal care visits | | |
| 1 | 92/1311 (7%) | 222/1239 (18%) |
| 2 | 222/1311 (17%) | 258/1239 (21%) |
| 3 | 423/1311 (32%) | 374/1239 (30%) |
| 4 | 380/1311 (29%) | 234/1239 (19%) |
| >5 | 194/1311 (15%) | 151/1239 (12%) |
| | | |
| Tetanus vaccination of nullipara* | | |
| TT11 | 223/232 (96%) | 195/208 (94%) |
| TT22 | 155/232 (72%) | 112/201 (56%) |
| Intermittent Preventive Treatment in pregnancy | | |
| IPTp1 | 1191/1311 (91%) | 1060/1239 (86%) |
| IPTp2 | 846/1311 (65%) | 640/1239 (52%) |
| Gestational age at last antenatal care visit | | |
| <16 | 17/1307 (1%) | 44/1230 (4%) |
| 17–26 | 140/1307 (11%) | 254/1230 (21%) |
| 27–35 | 784/1307 (60%) | 684/1230 (56%) |
| 36+ | 366/1307 (28%) | 248/1230 (20%) |
| Antepartum referral | 127/1311 (10%) | 57/1239 (5%) |
Data are n/N (%).*N = 264 intervention and 233 control. 52 not eligible. 68 not eligible.
Timing in gestational age of primary and secondary outcomes
| | | | | |
| Weeks of gestation at antenatal care visit no | | | | |
| 1 | 20.71 (4.69) | 20.10 (4.80) | 0.68 (-0.39–1.74) | 0.64 (-0.44–1.73) |
| 2 | 26.13 (4·04) | 25.92 (4.29) | 0.20 (-0.45–0.86) | 0.13 (-0.51–0.77) |
| 3 | 30.27 (3·50) | 30.41 (3.88) | -0.32 (-1.31–0.67) | -0.37 (-1.34–0.61) |
| 4 | 33.39 (3·05) | 32.79 (3.14) | 0.21 (-0.83–1.25) | 0.29 (-0.72–1.30) |
| 5 | 35.45 (2·45) | 34.77 (2.37) | 0.53 (-0.46–1.51) | 0.45 (-0.57–1.47) |
| | | | | |
| Weeks of gestation at tetatnus vaccination of nullipara*** | | | | |
| TT1 | 20.28 (5.08) | 19.46 (5.15) | 0.90 (-0 · 39–2.18) | -0.05 (-0.94–0.85) |
| TT2 | 25.53 (4.05) | 25.42 (4.78) | 0.07 (-1.10–1.24) | -0.84 (-1.93–0.26) |
| Weeks of gestation at Intermittent Preventive Treatment in pregnancy | | | | |
| IPTp1 | 23.75 (3.48) | 22.93 (3.84) | 0.80 (0.06-1.54) | 0.83 (0.06–1.59) |
| IPTp2 | 29.33 (3.25) | 28.90 (3.48) | 0.59 (-0.49–1.66) | 0.59 (-0.48–1.65) |
| Weeks of gestation at last antenatal care visit | 31.81 (4.90) | 30.15 (5.86) | 1.41 (-0.21–3.02) | 1.38 (-0.23–2.99) |
| Weeks of gestation at antepartum referral | 29.47 (6.38) | 26.67 (8.06) | 2.90 (-0.58–6.38) | 2.67 (-0.54–5.89) |
*Adjusted for within cluster effect.**Adjusted for significant variables associated with antenatal care attendance and within cluster effect.***N = 264 intervention and 233 control. 52 not eligible. 68 not eligible. SD Standard Deviation.
Association between mobile phone intervention and primary and secondary outcomes
| | | | | |
| Four or more antenatal care visits | 574/1311 (44%) | 385/1239 (31%) | 1.54 (0.80–2.96) | 2.39 (1.03–5.55) |
| | | | | |
| Tetatnus vaccination of nullipara*** | | | | |
| TT11 | 223/232 (96%) | 195/208 (94%) | 1.38 (0.39–4.87) | 1.58 (0.41–6.01) |
| TT22 | 155/232 (72%) | 112/201 (56%) | 1.67 (0.84–3.33) | 1.62 (0.81–3.26) |
| Intermittent Preventive Treatment in pregnancy | | | | |
| IPTp1 | 1191/1311 (91%) | 1060/1239 (86%) | 1.78 (0.49–6.52) | 1.10 (0.35–3.43) |
| IPTp2 | 846/1311 (65%) | 640/1239 (52%) | 1.69 (0.82–3.48) | 1.97 (0.98–3.94) |
| Gestational age 36 or more at last antenatal care visit | 366/1307 (28%) | 248/1230 (20%) | 1.45 (0.88–2.37) | 1.48 (0.89–2.45) |
| Antepartum referral | 127/1311 (10%) | 57/1239 (5%) | 1.58 (0.61–4.09) | 1.66 (0.68–4.06) |
*Adjusted for within cluster effect.**Adjusted for significant variables associated with antenatal care attendance, within cluster effect.***N = 264 intervention and 233 control. 52 not eligible. 68 not eligible.